Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.

Tytuł :
The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Autorzy :
Bogani G; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy. .
Leone Roberti Maggiore U; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Paolini B; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Diito A; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Martinelli F; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Lorusso D; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Raspagliesi F; Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
Pokaż więcej
Źródło :
Journal of gynecologic oncology [J Gynecol Oncol] 2019 Jan; Vol. 30 (1), pp. e4. Date of Electronic Publication: 2018 Sep 12.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: June 2011-: Seoul : Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe
Original Publication: Seoul : Korean Society of Gynecologic Oncology and Colposcopy, June 2008-
MeSH Terms :
Cystadenocarcinoma, Serous/*surgery
Cytoreduction Surgical Procedures/*adverse effects
Ovarian Neoplasms/*surgery
Aged ; Cystadenocarcinoma, Serous/mortality ; Cytoreduction Surgical Procedures/methods ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Neoplasm, Residual/epidemiology ; Ovarian Neoplasms/mortality ; Progression-Free Survival ; Proportional Hazards Models ; Retrospective Studies
References :
J Am Coll Surg. 2006 Nov;203(5):618-24. (PMID: 17084322)
Ann Oncol. 2012 Sep;23 Suppl 10:x111-7. (PMID: 22987944)
Obstet Gynecol. 2013 Aug;122(2 Pt 1):225-32. (PMID: 23969788)
Am J Clin Oncol. 2014 Dec;37(6):642-3. (PMID: 25412101)
Gynecol Oncol. 2015 Jan;136(1):25-9. (PMID: 25448453)
Gynecol Oncol. 2015 Jul;138(1):78-82. (PMID: 25969349)
Gynecol Oncol. 2016 Mar;140(3):457-62. (PMID: 26807488)
Am J Surg Pathol. 2016 May;40(5):627-35. (PMID: 26900814)
Ann Oncol. 2016 Apr;27 Suppl 1:i45-i49. (PMID: 27141071)
Gynecol Oncol. 2016 Nov;143(2):433-438. (PMID: 27581327)
Obstet Gynecol. 2017 Mar;129(3):439-447. (PMID: 28178043)
J Clin Oncol. 2017 Apr 1;35(10):1103-1111. (PMID: 28221866)
Gynecol Oncol. 2017 May;145(2):352-360. (PMID: 28228232)
Gynecol Oncol. 2017 Oct;147(1):85-91. (PMID: 28768570)
J Surg Oncol. 2018 Feb;117(2):236-244. (PMID: 28787528)
Ann Surg Oncol. 2017 Oct;24(11):3396-3405. (PMID: 28795373)
Harefuah. 2017 Aug;156(8):507-511. (PMID: 28853527)
Gynecol Oncol. 2017 Dec;147(3):503-508. (PMID: 28964622)
Int J Gynecol Cancer. 2017 Nov;27(9):1856-1862. (PMID: 29064913)
J Gynecol Oncol. 2018 Jan;29(1):e15. (PMID: 29185273)
Int J Gynecol Cancer. 2018 Mar;28(3):437-447. (PMID: 29465506)
J Gynecol Oncol. 2018 May;29(3):e40. (PMID: 29533023)
CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280)
Contributed Indexing :
Keywords: Cytoreduction Surgical Procedures; Drug Therapy; Gynecologic Surgical Procedures; Neoplasm Metastasis; Ovarian Neoplasms
Entry Date(s) :
Date Created: 20181128 Date Completed: 20190725 Latest Revision: 20200225
Update Code :
20210210
PubMed Central ID :
PMC6304412
DOI :
10.3802/jgo.2019.30.e4
PMID :
30479088
Czasopismo naukowe
Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC).
Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models.
Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) >1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16-6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29-7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29-1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12-7.74; p=0.027) were independently associated with an improved overall survival.
Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.
(Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies